CN102940801A - Traditional Chinese medicine composition for treating hypertension - Google Patents
Traditional Chinese medicine composition for treating hypertension Download PDFInfo
- Publication number
- CN102940801A CN102940801A CN 201210443202 CN201210443202A CN102940801A CN 102940801 A CN102940801 A CN 102940801A CN 201210443202 CN201210443202 CN 201210443202 CN 201210443202 A CN201210443202 A CN 201210443202A CN 102940801 A CN102940801 A CN 102940801A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- folium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 25
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 10
- 241000219780 Pueraria Species 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 230000001631 hypertensive effect Effects 0.000 claims description 14
- 241000218628 Ginkgo Species 0.000 claims description 13
- 235000011201 Ginkgo Nutrition 0.000 claims description 13
- 241000180649 Panax notoginseng Species 0.000 claims description 13
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 13
- 239000006071 cream Substances 0.000 claims description 12
- 239000009636 Huang Qi Substances 0.000 claims description 11
- 239000012141 concentrate Substances 0.000 claims description 6
- 230000006837 decompression Effects 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000019634 flavors Nutrition 0.000 claims description 6
- 239000012567 medical material Substances 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000000996 additive effect Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 235000005903 Dioscorea Nutrition 0.000 claims description 2
- 241000234273 Dioscorea Species 0.000 claims description 2
- 235000000504 Dioscorea villosa Nutrition 0.000 claims description 2
- 235000004347 Perilla Nutrition 0.000 claims description 2
- 244000124853 Perilla frutescens Species 0.000 claims description 2
- 241000545442 Radix Species 0.000 claims description 2
- 235000004879 dioscorea Nutrition 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 16
- 230000036772 blood pressure Effects 0.000 abstract description 11
- 208000024891 symptom Diseases 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 241001061264 Astragalus Species 0.000 abstract 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 235000002722 Dioscorea batatas Nutrition 0.000 abstract 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 abstract 1
- 240000001811 Dioscorea oppositifolia Species 0.000 abstract 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 abstract 1
- 244000194101 Ginkgo biloba Species 0.000 abstract 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 abstract 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 abstract 1
- 235000017784 Mespilus germanica Nutrition 0.000 abstract 1
- 244000182216 Mimusops elengi Species 0.000 abstract 1
- 235000000560 Mimusops elengi Nutrition 0.000 abstract 1
- 235000010676 Ocimum basilicum Nutrition 0.000 abstract 1
- 240000007926 Ocimum gratissimum Species 0.000 abstract 1
- 235000002789 Panax ginseng Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 235000007837 Vangueria infausta Nutrition 0.000 abstract 1
- 240000008042 Zea mays Species 0.000 abstract 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000005822 corn Nutrition 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000000361 pesticidal effect Effects 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 2
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229960003619 benazepril hydrochloride Drugs 0.000 description 2
- VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 230000003119 painkilling effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000002302 brachial artery Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating hypertension, which is characterized in that the composition is prepared with the following traditional Chinese medicine raw medicinal materials by weight parts: 2-15 parts of astragalus, 2-20 parts of salvia miltiorrhiza, 6-30 parts of pueraria, 3-15 parts of Chinese yam, 6-15 parts of medlar, 3-10 parts of ginkgo biloba, 6-15 parts of corn stigma, 3-15 parts of gynostemma, 3-20 parts of panax pseudoginseng, 10-30 parts of hawthorn and 10 parts of basil. The symptom of patients can be alleviated within a short time after the patients take the traditional Chinese medicine composition, the composition has the effects of reducing blood pressure and lipids; the efficacy is stable, the pesticide effect is exact, and the process is feasible. For the patients taking the composition for a long time, the side effect is small, the symptom is not easy to rebound after the patients stop taking the composition, and the cost is low.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, particularly a kind ofly treat hypertensive Chinese medicine composition, belong to pure technical field of Chinese medicines.
Background technology
Hypertension is a kind of take the arterial pressure rising as feature, can be functional with heart, blood vessel, brain and kidney and other organs or the systemic disease of organic change, it have essential hypertension and secondary hypertension minute.The reason of hypertension incidence is a lot, can be divided into two aspects of h and E.Hyperpietic's blood fat is mostly higher, and along with growth in the living standard, hypertensive prevalence rises year by year.Hypertension or the fuse cord of various diseases can make the onset risk of the diseases such as coronary heart disease, heart failure and kidney disease increase.Chinese medicine thinks, hypertension is because the result that the body imbalance between YIN and YANG produces.The deficiency of YIN is this, and yang hyperactivity is mark, and pathological changes is relevant with the five internal organs, the main heart, liver, the kidney of relating to, being designated as liver, is being kidney at this, and clinical manifestation is decreased in front with the moon take the hepatic and renal YIN deficiency or excessive rising of liver-YANG as cardinal symptom, yang hyperactivity in rear be main feature, arrived the course of disease later stage, develop into deficiency of both YIN and YANG.The conditioning viscera function is recovered equilibrium between yin and yang, is the hypertensive basic principle of traditional Chinese medical herbal treatment.The Therapeutic Method that does not get instant result and cure fully at present.Have clinically many antihypertensive drugs can control hypertension, but the Western medicine side effect is large, long-term taking can cause the damage to liver, kidney; The slow curative effect of existing Chinese medicine, DeGrain; They are all easily bounce-backs after drug withdrawal.
Summary of the invention
The object of the present invention is to provide a kind of hypertensive Chinese medicine composition for the treatment of, the patient can be eased symptom in the short time by taking behind this medicine, having to reduce blood pressure and blood fat easily rebounds, and expense is cheap.
Technical scheme of the present invention is: a kind ofly treat hypertensive Chinese medicine composition, it is characterized in that: it is formulated by following weight parts raw material of Chinese medicine medicine: Radix Astragali 2-15 part, Radix Salviae Miltiorrhizae 2-20 part, Radix Puerariae 6-30 part, Rhizoma Dioscoreae 3-15 part, Fructus Lycii 6-15 part, Folium Ginkgo 3-10 part, Stigma Maydis 6-15 part, Herb Gynostemmae Pentaphylli 3-15 part, Radix Notoginseng 3-20 part, Fructus Crataegi 10-30 part, Folium Perillae 3-10 part.
A kind ofly treat hypertensive Chinese medicine composition, it is characterized in that: it is formulated by following weight parts raw material of Chinese medicine medicine:
8 parts of the Radixs Astragali, 10 parts of Radix Salviae Miltiorrhizaes, 15 parts of Radix Puerariaes, 6 parts of Rhizoma Dioscoreaes, 10 parts of Fructus Lycii, 5 parts of Folium Ginkgos, 11 parts of Stigma Maydis, 7 parts of Herb Gynostemmae Pentaphylli, 8 parts of Radix Notoginseng, 20 parts of Fructus Crataegis, 8 parts of Folium Perillaes.This prescription is optimum formula.
Described a kind of preparation method for the treatment of hypertensive Chinese medicine composition, the method comprises the steps:
1), take by weighing raw material by following weight portion:
Get Radix Astragali 2-15 part, Radix Salviae Miltiorrhizae 2-20 part, Radix Puerariae 6-30 part, Rhizoma Dioscoreae 3-15 part, Fructus Lycii 6-15 part, Folium Ginkgo 3-10 part, Stigma Maydis 6-15 part, Herb Gynostemmae Pentaphylli 3-15 part, Radix Notoginseng 3-20 part, Fructus Crataegi 10-30 part, Folium Perillae 3-10 part;
2), get the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Puerariae, Rhizoma Dioscoreae, Fructus Lycii, Folium Ginkgo, Stigma Maydis, these a few flavor medical materials of Radix Notoginseng of above-mentioned weight portion, decoct with water twice, add 10 times of amounts of water for the first time, decocted 3 hours; For the second time add 8 times of amounts of water, decocted 2 hours, merge decoction liquor twice, filter, filtrate decompression concentrates, to temperature 60 ℃ the time, relative density is the thick paste of 1.20-1.25%; With thick paste 75-85 ℃ drying, dried cream was pulverized 100 mesh sieves, and powder gets dry extract;
3) get Fructus Crataegi, the Herb Gynostemmae Pentaphylli two flavor medical materials of above-mentioned weight portion, decoct with water twice, add 10 times of amounts of water for the first time, decocted 3 hours; For the second time add 8 times of amounts of water, decocted 2 hours, merge decoction liquor twice, filter, filtrate decompression concentrates, to temperature 60 ℃ the time, relative density is the thick paste of 1.20-1.25%; With thick paste 75-85 ℃ drying, dried cream was pulverized 100 mesh sieves, and powder gets dry extract;
4) with step 2) dried cream powder mix according to the equivalent incremental method with the dried cream powder of step 3), get mixture, get product.
Described finished product also can be mixed and made into tablet, pill, oral liquid or capsule with pharmaceutical carrier or additive.
Characteristics of the present invention are reasonable recipe, meet theory of Chinese medical science: the Radix Astragali has invigorating QI to consolidate the body surface resistance, diuresis poison holding, evacuation of pus, the effect of expelling pus and promoting granulation; Rhizoma Dioscoreae spleen reinforcing nourishing the stomach, the lung benefiting that promotes the production of body fluid, the kidney invigorating arresting seminal emission; The Radix Salviae Miltiorrhizae promoting blood flow to regulate menstruation, stasis-dispelling and pain-killing, removing heat from blood eliminating carbuncle, the relieving restlessness that clears away heart-fire, nourishing blood to tranquillize the mind; Fructus Lycii, nourishing the liver and kidney, replenishing vital essence to improve eyesight is used for the asthenia damage of essence, soreness of waist and knee joint, vertigo and tinnitus, interior-heat is quenched one's thirst, blood deficiency and yellow complexion, blurred vision is not clear; Folium Ginkgo is astringed the lung, and relievings asthma blood circulation promoting and blood stasis dispelling, pain relieving blood circulation promoting, prevention cardiovascular diseases; The Radix Notoginseng removing stasis to stop bleeding, the analgesic therapy of invigorating blood circulation.The kind hemostasis of merit again can blood stasis dispersing and fresh blood promoting, has hemostasis not stay the stasis of blood, and positive characteristics are not hindered in blood stasis dispelling.Can shorten hemorrhage and clotting time, have antiplatelet aggregation and thrombolytic effect; Can reduce myocardial oxygen consumption and coefficient of oxygen utilization, expansion of cerebral vascular strengthens cerebrovascular flow; Can improve humoral immune function, have analgesia, antiinflammatory, the anti-ageing effect of waiting for a long time.Radix Puerariae have the good reputation of " Asia Radix Ginseng ", Amylum Puerariae Radicis is referred to as " long-lived powder ", according to authoritative data books such as Compendium of Material Medica, " Chinese medicine voluminous dictionary ", " functional foods ", Radix Puerariae and goods thereof relieve inflammation or internal heat, toxin expelling, blood fat reducing, blood pressure lowering, cholesterol reducing, blood sugar lowering, fat-reducing, relieving constipation, prevention alzheimer disease, prevent arteriosclerosis, prevent the good effect of the cardiovascular and cerebrovascular diseases such as cerebral thrombosis.Modern medicine study shows: the isoflavonoid puerarin in the Radix Puerariae has significant curative effect to hypertension, hyperlipidemia, hyperglycemia and cardiovascular and cerebrovascular disease.Blood vessel dilating Radix Puerariae total flavones and puerarin can improve the oxygen metabolism of cardiac muscle, myocardial metabolism is produced beneficial effect, and the energy blood vessel dilating improves microcirculation simultaneously, reduce vascular resistance, blood flow is increased, thus available control myocardial ischemia, myocardial infarction, arrhythmia, hypertension, diabetes, the diseases such as arteriosclerosis.Fructus Crataegi has the increase myotility, increases cardiac output, the effect of decreasing heart rate.The increase coronary flow is arranged, reduce the effect of myocardial oxygen consumption and myocardium coefficient of oxygen utilization.The Nutritional myocardium blood flow amount there is certain increasing action.More lasting hypotensive effect is arranged.More sure effect for reducing fat is arranged.The Herb Gynostemmae Pentaphylli blood pressure lowering, blood fat reducing, blood sugar lowering, arteriosclerosis, inhibition thrombosis, Cardiovarscular; Calm the nerves and nourish one's nature, slow down aging improves mental activity, improves cerebral function; The activating human body normal cell, fat, the strengthening the spleen and stomach of losing weight, solution are tired, calmness are arranged, hypnosis, antipsycholic action; Strengthen the activity of blood of human body medium-sized lymphocyte, strengthen the immunologic function of human body; Eliminate the toxic and side effects of hormone medicine.Folium Perillae, relieving the exterior syndrome by diaphoresis, regulating the flow of QI to ease the stomach, solving toxin of fish and crab.
In sum, characteristics of the present invention are blood circulation promoting and blood stasis dispelling, circulation of qi promoting hemostasis, stasis-dispelling and pain-killing; Have hypertension and hyperlipemia, improve microcirculation, atherosclerosis suppresses thrombosis.The patient can be eased symptom in the short time by taking behind this medicine, has to reduce blood pressure and its stable curative effect of effect of blood fat, and drug effect is definite, feasible process.During patient's long-term taking, side effect is little, is not easy bounce-back after the drug withdrawal, and expense is cheap.
The specific embodiment
Below by the specific embodiment that provides the present invention can be described clearly further, but not as a limitation of the invention.
Embodiment 1
1) gets Radix Astragali 8g, Radix Salviae Miltiorrhizae 10g, Radix Puerariae 15g, Rhizoma Dioscoreae 6g, Fructus Lycii 10g, Folium Ginkgo 5g, Stigma Maydis 11g, Herb Gynostemmae Pentaphylli 7g, Radix Notoginseng 8g, Fructus Crataegi 20g, Folium Perillae 8g.
2), get the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Puerariae, Rhizoma Dioscoreae, Fructus Lycii, Folium Ginkgo, Stigma Maydis, these a few flavor medical materials of Radix Notoginseng of above-mentioned weight, decoct with water twice, for the first time add 10 times of amounts of water, decocted 3 hours; For the second time add 8 times of amounts of water, decocted 2 hours, merge decoction liquor twice, filter, filtrate decompression concentrates, to temperature 60 ℃ the time, relative density is the thick paste of 1.20-1.25%; With thick paste 75-85 ℃ drying, dried cream was pulverized 100 mesh sieves, and powder gets dry extract;
3) get Fructus Crataegi, the Herb Gynostemmae Pentaphylli two flavor medical materials of above-mentioned weight, decoct with water twice, add 10 times of amounts of water for the first time, decocted 3 hours; For the second time add 8 times of amounts of water, decocted 2 hours, merge decoction liquor twice, filter, filtrate decompression concentrates, to temperature 60 ℃ the time, relative density is the thick paste of 1.20-1.25%; With thick paste 75-85 ℃ drying, dried cream was pulverized 100 mesh sieves, and powder gets dry extract;
4) with step 2) dried cream powder mix according to the equivalent incremental method with the dried cream powder of step 3), get mixture, get product.
Incapsulate and be: capsule.
Using method: every day 3 times, each 2.
Embodiment 2
Get Radix Astragali 2g, Radix Salviae Miltiorrhizae 2g, Radix Puerariae 6g, Rhizoma Dioscoreae 3g, Fructus Lycii 6g, Folium Ginkgo 3g, Stigma Maydis 6g, Herb Gynostemmae Pentaphylli 3g, Radix Notoginseng 3g, Fructus Crataegi 10g, Folium Perillae 3g.
Preparation and application is basic identical with embodiment 1.Difference is: add an amount of adjuvant: dextrin, carboxymethyl starch sodium, magnesium stearate are made tablet.
Embodiment 3
Get Radix Astragali 15g, Radix Salviae Miltiorrhizae 20g, Radix Puerariae 30g, Rhizoma Dioscoreae 15g, Fructus Lycii 15g, Folium Ginkgo 10g, Stigma Maydis 15g, Herb Gynostemmae Pentaphylli 15g, Radix Notoginseng 20g, Fructus Crataegi 30g, Folium Perillae 10g.
Preparation and application is with embodiment 1.
Described finished product also can with pharmaceutical carrier or additive mf mass pil, oral liquid.
In order to show the therapeutic effect of medicine of the present invention, the present invention has carried out clinical trial.
A kind of clinical trial for the treatment of hypertensive Chinese medicine composition proposed by the invention is as follows:
Select age 48-58 year patient 120 examples, 53 years old mean age, course of disease April-1 year, average course of disease 7 months.The patient did not accept other treatment before this treatment, survey its blood pressure and all exceed normal value.28 days is a course for the treatment of, carries out symptom score after 28 days.Among the 120 routine patients, 20 examples (being called treatment group 1) adopt the medicine of the embodiment of the invention 1; 20 examples (being called treatment group 2) adopt the medicine of the embodiment of the invention 2; 20 examples (being called treatment group 3) adopt the medicine of the embodiment of the invention 3; 20 examples (being called contrast A group) adopt Benazepril hydrochloride contents in tablets; 20 examples (being called contrast B group) adopt blood pressure decreasing capsule; 20 examples (being called contrast C group) are not carried out Drug therapy.The zest environment is avoided in during this time patient's smoking cessation, is careful in one's diet and has a rest.
Adopt the Benazepril hydrochloride contents in tablets using method to be: once a day, each a slice; The using method of employing blood pressure decreasing capsule is identical with Chinese medicine composition embodiment's 1 of the present invention.
Therapeutic outcome:
The pressure value that hypertensive diagnosis is measured according to the clinic adopts approved mercury column or electric sphygmomanometer, upper arm brachial artery position blood pressure when measuring quiet rest seat.Also should measure in case of necessity horizontal position and erect position blood pressure.The effective criterion of hypertension: be normal value 130/85mmHg during measurement.The bounce-back standard is after the drug withdrawal: blood pressure exceeds normal value 130/85mmHg when referring to measure after the drug withdrawal.
Treat after 28 days, therapeutic effect relatively sees Table 1.
Table 1 embodiment of the invention 1 treatment effect comparison after 28 days
By as seen from Table 1, adopt the treatment group 1-3 effective percentage of the made Chinese medicine composition of the present invention apparently higher than contrast B and C group, the bounce-back rate also is starkly lower than contrast B and C group after the drug withdrawal, and the routine number of bounce-back only has treatment group 2 one examples after the treatment group 1-3 drug withdrawal; Although contrast A group effective percentage is higher than other several groups but bounce-back example number after patient's drug withdrawal up to 11 examples, apparently higher than treatment group 1-3.The result shows that the whole structure of the treatment of using treatment group 1-3 is good, is not easy bounce-back after the drug withdrawal.Wherein, adopt the best results of the treatment group 1 of embodiment 1.
Claims (4)
1. treat hypertensive Chinese medicine composition for one kind, it is characterized in that: it is formulated by following weight parts raw material of Chinese medicine medicine: Radix Astragali 2-15 part, Radix Salviae Miltiorrhizae 2-20 part, Radix Puerariae 6-30 part, Rhizoma Dioscoreae 3-15 part, Fructus Lycii 6-15 part, Folium Ginkgo 3-10 part, Stigma Maydis 6-15 part, Herb Gynostemmae Pentaphylli 3-15 part, Radix Notoginseng 3-20 part, Fructus Crataegi 10-30 part, Folium Perillae 3-10 part.
2. a kind of hypertensive Chinese medicine composition for the treatment of according to claim 1, its feature: it is formulated by following weight parts raw material of Chinese medicine medicine:
8 parts of the Radixs Astragali, 10 parts of Radix Salviae Miltiorrhizaes, 15 parts of Radix Puerariaes, 6 parts of Rhizoma Dioscoreaes, 10 parts of Fructus Lycii, 5 parts of Folium Ginkgos, 11 parts of Stigma Maydis, 7 parts of Herb Gynostemmae Pentaphylli, 8 parts of Radix Notoginseng, 20 parts of Fructus Crataegis, 8 parts of Folium Perillaes.
3. a kind of preparation method for the treatment of hypertensive Chinese medicine composition according to claim 1, the method comprises the steps:
1), take by weighing raw material by following weight portion:
Get Radix Astragali 2-15 part, Radix Salviae Miltiorrhizae 2-20 part, Radix Puerariae 6-30 part, Rhizoma Dioscoreae 3-15 part, Fructus Lycii 6-15 part, Folium Ginkgo 3-10 part, Stigma Maydis 6-15 part, Herb Gynostemmae Pentaphylli 3-15 part, Radix Notoginseng 3-20 part, Fructus Crataegi 10-30 part, Folium Perillae 3-10 part;
2), get the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Puerariae, Rhizoma Dioscoreae, Fructus Lycii, Folium Ginkgo, Stigma Maydis, these a few flavor medical materials of Radix Notoginseng of above-mentioned weight portion, decoct with water twice, add 10 times of amounts of water for the first time, decocted 3 hours; For the second time add 8 times of amounts of water, decocted 2 hours, merge decoction liquor twice, filter, filtrate decompression concentrates, to temperature 60 ℃ the time, relative density is the thick paste of 1.20-1.25%; With thick paste 75-85 ℃ drying, dried cream was pulverized 100 mesh sieves, and powder gets dry extract;
3) get Fructus Crataegi, the Herb Gynostemmae Pentaphylli two flavor medical materials of above-mentioned weight portion, decoct with water twice, add 10 times of amounts of water for the first time, decocted 3 hours; For the second time add 8 times of amounts of water, decocted 2 hours, merge decoction liquor twice, filter, filtrate decompression concentrates, to temperature 60 ℃ the time, relative density is the thick paste of 1.20-1.25%; With thick paste 75-85 ℃ drying, dried cream was pulverized 100 mesh sieves, and powder gets dry extract;
4) with step 2) dried cream powder mix according to the equivalent incremental method with the dried cream powder of step 3), get mixture, get product.
4. a kind of preparation method for the treatment of hypertensive Chinese medicine composition according to claim 3, it is characterized in that: described finished product also can be mixed and made into tablet, pill, oral liquid or capsule with pharmaceutical carrier or additive.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210443202 CN102940801A (en) | 2012-11-08 | 2012-11-08 | Traditional Chinese medicine composition for treating hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210443202 CN102940801A (en) | 2012-11-08 | 2012-11-08 | Traditional Chinese medicine composition for treating hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102940801A true CN102940801A (en) | 2013-02-27 |
Family
ID=47723861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210443202 Withdrawn CN102940801A (en) | 2012-11-08 | 2012-11-08 | Traditional Chinese medicine composition for treating hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102940801A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104689105A (en) * | 2015-02-11 | 2015-06-10 | 陕西健驰生物药业有限公司 | Medicine and food homologous plant product and preparation method thereof |
| CN104782848A (en) * | 2015-05-11 | 2015-07-22 | 广西梧州茂圣茶业有限公司 | Liubao (Chinese character) tea-containing composition with hypoglycemic function |
| CN104814220A (en) * | 2015-05-20 | 2015-08-05 | 陈世良 | Radix puerariae mixed tea for disease treatment and health care and making method thereof |
| CN106109708A (en) * | 2016-08-05 | 2016-11-16 | 李玲玲 | One treats thick blood fat drink tea Chinese medicine composition and preparation method thereof |
| CN107582896A (en) * | 2017-10-11 | 2018-01-16 | 广西昌弘制药有限公司 | It is a kind of that there is preparation for reducing blood pressure and blood lipoid effect and preparation method thereof |
| CN108669541A (en) * | 2018-05-15 | 2018-10-19 | 吉林省白山本苜药业有限公司 | With anticancer, improves the immunity of the human body, slows down aging, the health food and preparation method thereof of lower hyperlipidemia, hypertension, hyperglycemia function |
| CN109420156A (en) * | 2017-08-26 | 2019-03-05 | 杨振峰 | A kind of drug of thrombolysis lipid-lowering row bolt |
| CN109793867A (en) * | 2017-11-14 | 2019-05-24 | 仝二法 | Blood fat-reducing blood pressure-decreasing medicinal herb tea |
| CN113905679A (en) * | 2019-05-20 | 2022-01-07 | 美敦力瓦斯科尔勒公司 | Selection of hypertensive patients for treatment by renal denervation |
-
2012
- 2012-11-08 CN CN 201210443202 patent/CN102940801A/en not_active Withdrawn
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104689105A (en) * | 2015-02-11 | 2015-06-10 | 陕西健驰生物药业有限公司 | Medicine and food homologous plant product and preparation method thereof |
| CN104782848A (en) * | 2015-05-11 | 2015-07-22 | 广西梧州茂圣茶业有限公司 | Liubao (Chinese character) tea-containing composition with hypoglycemic function |
| CN104814220A (en) * | 2015-05-20 | 2015-08-05 | 陈世良 | Radix puerariae mixed tea for disease treatment and health care and making method thereof |
| CN106109708A (en) * | 2016-08-05 | 2016-11-16 | 李玲玲 | One treats thick blood fat drink tea Chinese medicine composition and preparation method thereof |
| CN109420156A (en) * | 2017-08-26 | 2019-03-05 | 杨振峰 | A kind of drug of thrombolysis lipid-lowering row bolt |
| CN107582896A (en) * | 2017-10-11 | 2018-01-16 | 广西昌弘制药有限公司 | It is a kind of that there is preparation for reducing blood pressure and blood lipoid effect and preparation method thereof |
| CN109793867A (en) * | 2017-11-14 | 2019-05-24 | 仝二法 | Blood fat-reducing blood pressure-decreasing medicinal herb tea |
| CN109793867B (en) * | 2017-11-14 | 2022-07-05 | 仝二法 | Lipid-lowering and pressure-lowering medicinal tea |
| CN108669541A (en) * | 2018-05-15 | 2018-10-19 | 吉林省白山本苜药业有限公司 | With anticancer, improves the immunity of the human body, slows down aging, the health food and preparation method thereof of lower hyperlipidemia, hypertension, hyperglycemia function |
| CN113905679A (en) * | 2019-05-20 | 2022-01-07 | 美敦力瓦斯科尔勒公司 | Selection of hypertensive patients for treatment by renal denervation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102940801A (en) | Traditional Chinese medicine composition for treating hypertension | |
| CN104645091A (en) | Capsule for treating hypertension | |
| CN101104048B (en) | Compound medicine for pulse generating and treating coronary heart disease | |
| CN102172385B (en) | A kind of Chinese medicine preparation with enhancing immunity, blood sugar lowering and effect for reducing blood fat | |
| CN105920514A (en) | Traditional Chinese medicinal composition for treating metabolic syndrome | |
| CN101095768B (en) | Chinese traditional medicine capsule for treating primary hypertension for persons in middle and old age | |
| CN105031517A (en) | Dendrobium officinale healthcare tea capable of reducing blood fat, blood sugar, and blood pressure and preparation method thereof | |
| CN103479754B (en) | Hypotensive drug and preparation method thereof | |
| CN102940730A (en) | Traditional Chinese medicine for treating hypertension | |
| CN103705860B (en) | A kind of Chinese medicine composition for the treatment of infant jaundice and preparation method thereof | |
| CN102671056B (en) | Chinese medicinal composition for treating hepatitis and preparation method thereof | |
| CN104524003A (en) | Traditional Chinese medicine composition with golden camellia and radix pueraiae | |
| CN103725587A (en) | Sealwort and hawthorn vinegar and production method thereof | |
| CN102266481B (en) | Chinese medicinal preparation for treating chronic cerebral circulation insufficiency | |
| CN1183936C (en) | Medicine for treating hypertension and method for preparing medicinal tea thereof | |
| CN106389892A (en) | Food therapy powder and preparation method thereof | |
| CN106343413A (en) | Health food for assisting reduction of blood glucose, blood pressure and blood lipid | |
| CN105833055A (en) | Traditional Chinese medicine composition for treating hypertension, hyperlipidemia and hyperglycemia and preparing method and application thereof | |
| CN112641878A (en) | Traditional Chinese medicine composition for treating anemia and preparation method thereof | |
| CN105343506A (en) | Method for preparing composition for treating type-2 diabetes | |
| CN105796755A (en) | Traditional Chinese medicinal composition for treating diabetic nephropathy | |
| CN104127670A (en) | Traditional Chinese medicine decoction for treating arrhythmia | |
| CN104189615B (en) | Traditional Chinese medicine preparation for treating metrorrhagia and metrostaxis, and preparation method of traditional Chinese medicine preparation | |
| CN102772665B (en) | Traditional Chinese medicine preparation for treating yin deficiency and internal heat type vital myocarditis and preparation method thereof | |
| CN1259075C (en) | Chinese traditional medicinal composition Weitashen for replenishing qi, invigorating spleen, calming heart and tranquilizing mind |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C04 | Withdrawal of patent application after publication (patent law 2001) | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20130227 |